RecruitingEarly Phase 1NCT00992901

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery


Sponsor

The University of Texas Health Science Center at San Antonio

Enrollment

160 participants

Start Date

Oct 1, 2009

Study Type

INTERVENTIONAL

Conditions

Summary

RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atropine, a drug called Exendin-(9-39), and others for people with hypoglycemia and post bariatricsurgery. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGExendin-(9-39)

A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion

DRUGAtropine

A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism

DRUGGLP-1 and GIP

A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones


Locations(2)

Texas Diabetes Institute - University Health System

San Antonio, Texas, United States

South Texas Veterans Health Care System

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00992901


Related Trials